NCT06268145View on ClinicalTrials.gov

ECC5004 RBA FE Study in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

February 6, 2024

Primary Completion Date

March 29, 2024

Study Completion Date

March 29, 2024

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

ECC5004

A single dose tablet of 50 mg of the current tablet formulation (F1) or new tablet formulation (F2) administered orally.

Trial Locations (1)

92801

Eccogene Investigational Site, Anaheim

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Eccogene

INDUSTRY

NCT06268145 - ECC5004 RBA FE Study in Healthy Participants | Biotech Hunter | Biotech Hunter